Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Zentynel Frontier Investments is the first venture capital fund specialized in biotechnology in Latin America. Founded in 2019 through a collaborative vision between Fundación Ciencia & Vida and Venturance Alternative Assets, Zentynel aims to transform innovative science into scalable businesses. The firm operates with a fund size of $50 million and has invested in 17 companies across six countries, catalyzing over $100 million in co-investments. This unique positioning allows Zentynel to bridge the significant capital gap in the biotechnology sector within the region.
The firm is headquartered in Santiago, Chile, and has established itself as a key player in the Latin American venture capital landscape. By combining capital with scientific knowledge and operational experience, Zentynel supports entrepreneurs in various stages of their business development. The firm’s notable milestones include its active role in the biotechnology sector and its commitment to fostering growth in health technology.
Zentynel Frontier Investments focuses on early-stage ventures with global ambitions that maintain strong ties to Latin America. The firm invests primarily in sectors such as human and animal health, digital health, AI-driven platforms, agrotechnology, food technology, and environmental biotechnology. Typical investments range from $1 million to $2 million, with 25-30% of the fund reserved for follow-on investments. This strategy allows Zentynel to support its portfolio companies through various stages of growth.
The firm actively seeks out innovative startups that leverage the region's scientific talent and biodiversity. Zentynel emphasizes the importance of operational assistance, international networks, and strategic advice to help founders accelerate growth and maximize their impact. This hands-on approach distinguishes Zentynel from other venture capital firms, as they prioritize not only financial investment but also the operational success of their portfolio companies.
Zentynel Frontier Investments has built a diverse portfolio of 17 companies that address various health, sustainability, and food system challenges. Notable companies in their portfolio include:
This portfolio reflects Zentynel's commitment to addressing pressing health and sustainability challenges through innovative biotechnology solutions.
Cristián Hernández - General Partner. He has over 20 years of experience in biotech investment and development, previously serving as CEO of Fundación Ciencia & Vida and Nova Mineralis.
Pablo Fernández - General Partner. He brings extensive experience in venture capital and has been involved in multiple successful investments in the biotech sector.
Roberto Loehnert - General Partner. He co-founded Venturance Investments and has a strong background in managing venture capital funds.
Bernardita Méndez - General Partner. She is a co-founder of Zentynel and has deep connections to Fundación Ciencia & Vida, enhancing the firm's deal flow.
Pablo Valenzuela - General Partner. He is the Director of Alerce Fund and serves on the boards of several companies, contributing to Zentynel's strategic direction.
Martha Laura López - Operating Partner. She provides operational support to portfolio companies, leveraging her extensive experience in the biotech industry.
Natanael Leitão, Ph.D. - Operating Partner. He brings a scientific perspective to the investment process, ensuring that the firm's investments are grounded in solid research and innovation.
To pitch Zentynel Frontier Investments, founders should visit their website at zentynel.com. It is recommended to include a comprehensive business plan in the pitch deck, highlighting the startup's alignment with Zentynel's focus areas in biotechnology and health technology. Founders should also detail their team’s expertise and the unique value proposition of their product or service.
While Zentynel does not specify a formal application form, a well-structured pitch deck is crucial. Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can enhance the chances of securing a meeting with the investment team.
In March 2025, Zentynel Frontier Investments made a significant investment in Asclepii, a company focused on medical supplies and regenerative medicine. This investment aligns with Zentynel's commitment to supporting innovative biotech ventures in Latin America.
In June 2022, Zentynel participated in Autem Therapeutics' $10 million Series A-1 financing round, which focuses on bioelectric cancer treatment. This investment demonstrates Zentynel's active role in the biotechnology sector and its dedication to advancing healthcare solutions.
As of 2023, Zentynel is in the process of raising Fund II, targeting a size of $50 million, which will continue to focus on biotechnology and health technology investments.
What are Zentynel's investment criteria?
Zentynel invests in early-stage ventures with strong ties to Latin America, focusing on biotechnology, healthcare, agtech, and digital health. They typically invest between $1 million and $2 million per company.
How can founders apply or pitch to Zentynel?
Founders can pitch their ideas through the Zentynel website at zentynel.com. It is advisable to include a detailed business plan and information on how the startup aligns with Zentynel's focus areas.
What makes Zentynel different from other venture capital firms?
Zentynel is the first VC fund specialized in biotechnology in Latin America, combining capital with scientific expertise and operational support to help entrepreneurs succeed.
What is Zentynel's geographic scope?
Zentynel primarily focuses on investments in Latin America, but they also consider opportunities in North America and Europe that align with their investment thesis.
What kind of post-investment involvement does Zentynel have?
Zentynel provides direct operational assistance, access to international networks, and strategic advice to help portfolio companies accelerate growth and maximize their impact.
What is the size of Zentynel's fund?
Zentynel's current fund size is $50 million, with a focus on biotechnology and health technology investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.